NCT01875666View on ClinicalTrials.gov

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 5, 2013

Primary Completion Date

December 19, 2016

Study Completion Date

December 19, 2016

Conditions
Breast Neoplasms
Interventions
DRUG

Trastuzumab

8 mg/kg IV, single dose

DRUG

pertuzumab

840 mg IV single dose

DRUG

lapatinib

1000 mg daily for 7 days

Trial Locations (5)

27599

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill

35294

University of Alabama at Birmingham, Birmingham

46202

IU Simon Cancer Center, Indianapolis

02215

Dana Farber Cancer Institute, Boston

77030-4008

MD Anderson, Houston

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Susan G. Komen Breast Cancer Foundation

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT01875666 - Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib | Biotech Hunter | Biotech Hunter